Sandoz: Pioneering Access for Patients with Ambitious Biosimilar Strategy

Sandoz, the global leader in generic and biosimilar medicines, is set to confirm its strategic roadmap and highlight pipeline catalysts at the 43rd Annual J.P. Morgan Healthcare Conference. The company's ambitious biosimilar strategy, coupled with its diverse pipeline, positions Sandoz to capitalize on the growing demand for affordable treatments and deliver value to patients and healthcare systems.

Sandoz's biosimilar pipeline diversity contributes to its growth strategy by addressing a wide range of therapeutic areas and diseases. As of 2025, Sandoz has an industry-leading pipeline of 28 biosimilars, covering various indications such as chronic inflammatory diseases, multiple sclerosis, osteoporosis, and retinal diseases. This diversity allows Sandoz to cater to a broader patient population and healthcare systems, ultimately driving its growth. For instance, Sandoz plans to launch four biosimilars in 2025, including Pyzchiva® (ustekinumab) for chronic inflammatory diseases, Tyruko® (natalizumab) for multiple sclerosis, Wyost®/Jubbonti® (denosumab) for osteoporosis, and Afqlir® (aflibercept) for retinal diseases. By providing biosimilar alternatives for these diverse therapy areas, Sandoz is delivering on its purpose of pioneering access for patients and fueling its future growth.

Sandoz's ambition to lead the US biosimilar market is driven by several key factors. The US biosimilar market presents a significant opportunity for Sandoz, with reference medicines worth more than USD 400 billion in sales due to lose exclusivity from 2029 onwards, and nearly half of this opportunity in the biosimilar segment. As the global leader, Sandoz has an industry-leading pipeline of 28 molecules, which is both diverse and covers a significant addressable market value. This strong pipeline positions Sandoz to become the leader in US biosimilars. Sandoz currently ranks #4 in biosimilars in the US but has the ambition to become #1. The company plans five biosimilar launches in the mid-term, including three in the US in 2025, which will help it achieve sustainable leadership in the US biosimilar segment.

Sandoz's GLP-1 strategy aligns with the market's growing demand for affordable diabetes treatments. The company has a clear and ambitious strategy in place to address the emerging opportunity in the GLP-1 segment. This strategy is crucial, as GLP-1 medicines represent the single largest opportunity in the generic space, with a significant market potential. By focusing on this segment, Sandoz is well-positioned to capitalize on the increasing demand for cost-effective diabetes treatments, ultimately delivering value to patients and healthcare systems.

In conclusion, Sandoz's biosimilar pipeline diversity, ambitious US market strategy, and GLP-1 focus position the company to capitalize on the growing demand for affordable treatments and deliver value to patients and healthcare systems. As Sandoz confirms its strategic roadmap and highlights pipeline catalysts at the 43rd Annual J.P. Morgan Healthcare Conference, investors can expect the company to continue its strong performance and drive growth in the biosimilar market.